Slow Release Pharmaceutical Composition Made of Microparticles

Abstract

Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: —D (v,0.1) is between 10 and 30 micrometers, —D (v,0.5) is between 30 and 70 micrometers, —D(v,0.9) is between 50 and 1 10 micrometers.

1 - 14 . (canceled) 
     
     
         15 . A method of treating prostate cancer in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising microparticles comprising triptorelin pamoate, wherein the microparticles are made of poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA comprises at least 75% lactide, and wherein the triptorelin pamoate is released from the pharmaceutical composition in an immediate amount within hours following injection and then constantly released over a period of at least 168 days. 
     
     
         16 . The method of  claim 15 , wherein the composition is administered once every 6 months to the patient. 
     
     
         17 . The method of  claim 15 , wherein the composition comprises two groups of microparticles. 
     
     
         18 . The method of  claim 17 , wherein at least one of the two group of microparticles is a group of microspheres. 
     
     
         19 . The method of  claim 18 , wherein one group of microparticles is microspheres and the second group of microparticles is microgranules. 
     
     
         20 . The method of  claim 17 , wherein the two groups of microparticles are a first group of microgranules and a second group of microgranules. 
     
     
         21 . The method of  claim 20 , wherein the first group of microgranules is a first formulation of microgranules comprising approximately 20% (w/w) of triptorelin pamoate mixed with approximately 80% (w/w) PLGA, wherein the PLGA in the first formulation contains approximately 85% lactide and 15% glycolide and the second group of microgranules is a second formulation of microgranules comprising approximately 12% (w/w) triptorelin pamoate mixed with approximately 88% (w/w) poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA in the second formulation contains approximately 75% lactide and 25% glycolide. 
     
     
         22 . The method of  claim 21 , wherein the first group of microgranules and the second group of microgranules are mixed to have a 50:50 dose ratio of triptorelin. 
     
     
         23 . The method of  claim 15 , wherein the pharmaceutical composition induces chemical castration in the patient over a six-month period of time. 
     
     
         24 . The method of  claim 15 , wherein the patient has advanced prostate cancer. 
     
     
         25 . A method of inducing chemical castration in a patient in need thereof comprising administering to the patient a pharmaceutical composition comprising microparticles comprising triptorelin pamoate, wherein the microparticles are made of poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA comprises at least 75% lactide, and wherein the triptorelin pamoate is released from the pharmaceutical composition in an immediate amount within hours following injection and then constantly released over a period of at least 168 days. 
     
     
         26 . The method of  claim 25 , wherein the composition is administered once every 6 months to the patient. 
     
     
         27 . The method of  claim 25 , wherein the composition comprises two groups of microparticles. 
     
     
         28 . The method of  claim 27 , wherein at least one of the two group of microparticles is a group of microspheres. 
     
     
         29 . The method of  claim 28 , wherein one group of microparticles is microspheres and the second group of microparticles is microgranules. 
     
     
         30 . The method of  claim 27 , wherein the two groups of microparticles are a first group of microgranules and a second group of microparticles. 
     
     
         31 . The method of  claim 30 , wherein the first group of microgranules is a first formulation of microgranules comprising approximately 20% (w/w) of triptorelin pamoate mixed with approximately 80% (w/w) PLGA, wherein the PLGA in the first formulation contains approximately 85% lactide and 15% glycolide and the second group of microgranules is a second formulation of microgranules comprising approximately 12% (w/w) triptorelin pamoate mixed with approximately 88% (w/w) poly(D,L lactide-co-glycolide) (PLGA), wherein the PLGA in the second formulation contains approximately 75% lactide and 25% glycolide. 
     
     
         32 . The method of  claim 31 , wherein the first group of microgranules and the second group of microgranules are mixed to have a 50:50 dose ratio of triptorelin. 
     
     
         33 . The method of  claim 25 , wherein the patient has advanced prostate cancer.